Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs

Diabetes Care

Volumn 31, Issue 5, 2008, Pages 852-856

  Yang, Wenying ^a   Ji, Qiuhe ^b   Zhu, Dalong ^c   Yang, Jinkui ^d   Chen, Lulu ^e   Liu, Zhimin ^f   Yu, Demin ^g   Yan, Li ^h  

^a CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e UNION HOSPITAL   (China)

^f SECOND MILITARY MEDICAL UNIVERSITY   (China)

^g TIANJIN MEDICAL UNIVERSITY   (China)

^h SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; ORAL ANTIDIABETIC AGENT; ANTIDIABETIC AGENT; DRUG DERIVATIVE; INSULIN; INSULIN, ASP(B28)-;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETES CONTROL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; WEIGHT GAIN; ADOLESCENT; BLOOD; BLOOD GLUCOSE MONITORING; BODY MASS; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG COMBINATION; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; SAFETY;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; SAFETY;

EID: 48649094486     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc07-1992     Document Type: Article

References (12)

1. Nathan DM: Finding new treatments for diabetes: how many, how fast. how good? N EngJ Med 356:437-440, 2007
2. Raskin P, Matfin G, Schwartz SL, Chaykin L, Chu PL, Braceras R, Wynne A: Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: the ACTION study (Achieving Control Through Insulin plus Oral ageNts) Diabetes Obes Metab, 2007 (Epub ahead of print)
3. Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, Bode B, Garber A, the INITIATE Study Group: Initiation insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 28:260-265, 2005
4. Garber A, Wahlen J, Wahl T, Bressler P, Braceras R, Allen E, Jain R, the 1-2-3 Study Group: Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (the 1-2-3 study). Diabetes Obes Metab 8:58 -66, 2006
5. Matthews DR, Cull CA, Stratton IM, Hol-man RR, Turner RC: UKPDS 26: sulpho-nylurea failure in noninsulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.Diabetes Med 15:297-303, 1998
6. American Diabetes Association: Standard of medical care in diabetes (Position Statement). Diabetes Care 27 (Suppl. 1):S15-S35, 2004
7. IDF Clinical Guidelines Task Force: Global guideline for type 2 diabetes: recomendations for standard, comprehensive, and minimal care. Diabet Med 23: 579-593, 2006
8. Pan C, Yang W, Jia W, Weng J, Tian H: Current diabetes care status in China: an observational survey study (DIABCARE 2006) (EASD abstract 1021).
9. Pan XR, Yang WY, Li GW, et al. Prevalence of diabetes and its risk factors in China, 1994. National Diabetes Prevention and Control Cooperative Group. Di-abetesCare 20(11):1664-1669, 1997
10. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR Sulfonylurea Inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective diabetes Study (UKPDS 57). Diabetes Care 25:330-336, 2002
11. 1c. Diabetes Care 26:881-885, 2003
12. UK Prospective Diabetes Study (UKPDS) Group: Intensive, blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). lancet 352:837-853, 1998